Patents by Inventor J. Holman

J. Holman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • URETERAL STENT
    Publication number: 20180272041
    Abstract: Provided is a ureteral stent comprising certain amount of ethylene-vinyl acetate polymer and a certain amount of an additive selected from barium sulfate, bismuth subcarbonate, bismuth oxychloride, a polyolefin elastomer, a thermoplastics elastomer, and a mixture thereof. The provided stent may have multiple layers such as inner layer and outer layer with each layer having different elastic modulus. Also provided is a method of making the aforementioned ureteral stent and a method of using the ureteral stent in treating kidney or bladder related diseases.
    Type: Application
    Filed: March 14, 2018
    Publication date: September 27, 2018
    Applicant: Gyrus ACMI, Inc. d/b/a Olympus Surgical Technologies America
    Inventors: Hui Tang, Thomas J. Holman, Judy L. Walish
  • Medical devices and related methods
    Patent number: 10052461
    Abstract: This disclosure relates to medical devices and related methods. In some embodiments, the methods include applying a material to the balloon and then removing the material from one or more regions of the balloon.
    Type: Grant
    Filed: March 20, 2014
    Date of Patent: August 21, 2018
    Assignee: BOSTON SCIENTIFIC SCIMED, INC.
    Inventors: Thomas J. Holman, James Lee Shippy, III, Afsar Ali
  • Antibody-SN-38 immunoconjugates with a CL2A linker
    Patent number: 10034950
    Abstract: The present invention concerns improved methods and compositions for preparing SN-38 conjugates of proteins or peptides, preferably immunoconjugates of antibodies or antigen-binding antibody fragments. More preferably, the SN-38 is attached to the antibody or antibody fragment using a CL2A linker, with 1-12, more preferably 6 or less, most preferably 1-5 SN-38 moieties per antibody or antibody fragment. Most preferably, the immunoconjugate is prepared in large scale batches, with various modifications to the reaction scheme to optimize yield and recovery in large scale. Other embodiments concern optimized dosages and/or schedules of administration of immunoconjugate to maximize efficacy for disease treatment and minimize side effects of administration.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: July 31, 2018
    Assignee: Immunomedics, Inc.
    Inventors: Serengulam V. Govindan, Jonathan B. Gale, Nicholas J. Holman, David M. Goldenberg
  • ANTIBODY-SN-38 IMMUNOCONJUGATES WITH A CL2A LINKER
    Publication number: 20180161440
    Abstract: The present invention concerns improved methods and compositions for preparing SN-38 conjugates of proteins or peptides, preferably immunoconjugates of antibodies or antigen-binding antibody fragments. More preferably, the SN-38 is attached to the antibody or antibody fragment using a CL2A linker, with 1-12, more preferably 6-8, alternatively 1-5 SN-38 moieties per antibody or antibody fragment. Most preferably, the immunoconjugate is prepared in large scale batches, with various modifications to the reaction scheme disclosed herein to optimize yield and recovery in large scale. Other embodiments concern optimized dosages and/or schedules of administration of immunoconjugate to maximize efficacy for disease treatment and minimize side effects of administration.
    Type: Application
    Filed: January 29, 2018
    Publication date: June 14, 2018
    Inventors: Serengulam V. Govindan, Jonathan B. Gale, Nicholas J. Holman, David M. Goldenberg
  • COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATMENTS OF IMMUNE RELATED DISEASES AND DISORDERS
    Publication number: 20180117148
    Abstract: Provided herein are methods, pharmaceutical compositions and kits with combination therapies including biopharmaceuticals and neuroregulatory medicines for the treatment of immune related diseases and disorders.
    Type: Application
    Filed: October 27, 2017
    Publication date: May 3, 2018
    Inventor: Andrew J. Holman
  • Brushless Direct Current Motor with Integrated Fan
    Publication number: 20180109164
    Abstract: Provided is a rotor assembly for a brushless direct current motor. The rotor assembly includes an insert which fits within an outer rotor cup. The insert locates the position of the magnets and secures them with extended features. Curved fan blades are integrated into the insert to provide improved airflow and cooling during rotation. The insert has features incorporated to reduce overall noise caused by air flow by having smooth transitions between mating surfaces and joints. A trench is incorporated within the insert to provide an overflow catch for excess adhesive when the magnet segments are “glued” into place.
    Type: Application
    Filed: October 13, 2016
    Publication date: April 19, 2018
    Applicant: SFEG Corp.
    Inventor: Steven J. Holman
  • Antibody-SN-38 immunoconjugates with a CL2A linker
    Patent number: 9931417
    Abstract: The present invention concerns improved methods and compositions for preparing SN-38 conjugates of proteins or peptides, preferably immunoconjugates of antibodies or antigen-binding antibody fragments. More preferably, the SN-38 is attached to the antibody or antibody fragment using a CL2A linker, with 1-12, more preferably 6-8, alternatively 1-5 SN-38 moieties per antibody or antibody fragment. Most preferably, the immunoconjugate is prepared in large scale batches, with various modifications to the reaction scheme disclosed herein to optimize yield and recovery in large scale. Other embodiments concern optimized dosages and/or schedules of administration of immunoconjugate to maximize efficacy for disease treatment and minimize side effects of administration.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: April 3, 2018
    Assignee: Immunomedics, Inc.
    Inventors: Serengulam V. Govindan, Jonathan B. Gale, Nicholas J. Holman, David M. Goldenberg
  • ANTIBODY-SN-38 IMMUNOCONJUGATES WITH A CL2A LINKER
    Publication number: 20180085469
    Abstract: The present invention concerns improved methods and compositions for preparing SN-38 conjugates of proteins or peptides, preferably immunoconjugates of antibodies or antigen-binding antibody fragments. More preferably, the SN-38 is attached to the antibody or antibody fragment using a CL2A linker, with 1-12, more preferably 6 or less, most preferably 1-5 SN-38 moieties per antibody or antibody fragment. Most preferably, the immunoconjugate is prepared in large scale batches, with various modifications to the reaction scheme to optimize yield and recovery in large scale. Other embodiments concern optimized dosages and/or schedules of administration of immunoconjugate to maximize efficacy for disease treatment and minimize side effects of administration.
    Type: Application
    Filed: November 14, 2017
    Publication date: March 29, 2018
    Inventors: Serengulam V. Govindan, Jonathan B. Gale, Nicholas J. Holman, David M. Goldenberg
  • Antibody-SN-38 immunoconjugates with a CL2A linker
    Patent number: 9855344
    Abstract: The present invention concerns improved methods and compositions for preparing SN-38 conjugates of proteins or peptides, preferably immunoconjugates of antibodies or antigen-binding antibody fragments. More preferably, the SN-38 is attached to the antibody or antibody fragment using a CL2A linker, with 1-12, more preferably 6 or less, most preferably 1-5 SN-38 moieties per antibody or antibody fragment. Most preferably, the immunoconjugate is prepared in large scale batches, with various modifications to the reaction scheme to optimize yield and recovery in large scale. Other embodiments concern optimized dosages and/or schedules of administration of immunoconjugate to maximize efficacy for disease treatment and minimize side effects of administration.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: January 2, 2018
    Assignee: Immunomedics, Inc.
    Inventors: Serengulam V. Govindan, Jonathan B. Gale, Nicholas J. Holman, David M. Goldenberg
  • ANTIBODY-SN-38 IMMUNOCONJUGATES WITH A CL2A LINKER
    Publication number: 20170165370
    Abstract: The present invention concerns improved methods and compositions for preparing SN-38 conjugates of proteins or peptides, preferably immunoconjugates of antibodies or antigen-binding antibody fragments. More preferably, the SN-38 is attached to the antibody or antibody fragment using a CL2A linker, with 1-12, more preferably 6 or less, most preferably 1-5 SN-38 moieties per antibody or antibody fragment. Most preferably, the immunoconjugate is prepared in large scale batches, with various modifications to the reaction scheme to optimize yield and recovery in large scale. Other embodiments concern optimized dosages and/or schedules of administration of immunoconjugate to maximize efficacy for disease treatment and minimize side effects of administration.
    Type: Application
    Filed: February 24, 2017
    Publication date: June 15, 2017
    Inventors: Serengulam V. Govindan, Jonathan B. Gale, Nicholas J. Holman, David M. Goldenberg
  • Antibody-SN-38 immunoconjugates with a CL2A linker
    Patent number: 9629926
    Abstract: The present invention concerns improved methods and compositions for preparing SN-38 conjugates of proteins or peptides, preferably immunoconjugates of antibodies or antigen-binding antibody fragments. More preferably, the SN-38 is attached to the antibody or antibody fragment using a CL2A linker, with 1-12, more preferably 6 or less, most preferably 1-5 SN-38 moieties per antibody or antibody fragment. Most preferably, the immunoconjugate is prepared in large scale batches, with various modifications to the reaction scheme to optimize yield and recovery in large scale. Other embodiments concern optimized dosages and/or schedules of administration of immunoconjugate to maximize efficacy for disease treatment and minimize side effects of administration.
    Type: Grant
    Filed: May 23, 2016
    Date of Patent: April 25, 2017
    Assignee: Immunomedics, Inc.
    Inventors: Serengulam V. Govindan, Jonathan B. Gale, Nicholas J. Holman, David M. Goldenberg
  • ANTIBODY-SN-38 IMMUNOCONJUGATES WITH A CL2A LINKER
    Publication number: 20160303253
    Abstract: The present invention concerns improved methods and compositions for preparing SN-38 conjugates of proteins or peptides, preferably immunoconjugates of antibodies or antigen-binding antibody fragments. More preferably, the SN-38 is attached to the antibody or antibody fragment using a CL2A linker, with 1-12, more preferably 6-8, alternatively 1-5 SN-38 moieties per antibody or antibody fragment. Most preferably, the immunoconjugate is prepared in large scale batches, with various modifications to the reaction scheme disclosed herein to optimize yield and recovery in large scale. Other embodiments concern optimized dosages and/or schedules of administration of immunoconjugate to maximize efficacy for disease treatment and minimize side effects of administration.
    Type: Application
    Filed: June 29, 2016
    Publication date: October 20, 2016
    Inventors: Serengulam V. Govindan, Jonathan B. Gale, Nicholas J. Holman, David M. Goldenberg
  • ANTIBODY-SN-38 IMMUNOCONJUGATES WITH A CL2A LINKER
    Publication number: 20160256562
    Abstract: The present invention concerns improved methods and compositions for preparing SN-38 conjugates of proteins or peptides, preferably immunoconjugates of antibodies or antigen-binding antibody fragments. More preferably, the SN-38 is attached to the antibody or antibody fragment using a CL2A linker, with 1-12, more preferably 6 or less, most preferably 1-5 SN-38 moieties per antibody or antibody fragment. Most preferably, the immunoconjugate is prepared in large scale batches, with various modifications to the reaction scheme to optimize yield and recovery in large scale. Other embodiments concern optimized dosages and/or schedules of administration of immunoconjugate to maximize efficacy for disease treatment and minimize side effects of administration.
    Type: Application
    Filed: May 23, 2016
    Publication date: September 8, 2016
    Inventors: Serengulam V. Govindan, Jonathan B. Gale, Nicholas J. Holman, David M. Goldenberg
  • Antibody-SN-38 immunoconjugates with a CL2A linker
    Patent number: 9375489
    Abstract: The present invention concerns improved methods and compositions for preparing SN-38 conjugates of proteins or peptides, preferably immunoconjugates of antibodies or antigen-binding antibody fragments. More preferably, the SN-38 is attached to the antibody or antibody fragment using a CL2A linker, with 1-12, more preferably 6 or less, most preferably 1-5 SN-38 moieties per antibody or antibody fragment. Most preferably, the immunoconjugate is prepared in large scale batches, with various modifications to the reaction scheme to optimize yield and recovery in large scale. Other embodiments concern optimized dosages and/or schedules of administration of immunoconjugate to maximize efficacy for disease treatment and minimize side effects of administration.
    Type: Grant
    Filed: July 1, 2015
    Date of Patent: June 28, 2016
    Assignee: Immunomedics, Inc.
    Inventors: Serengulam V. Govindan, Jonathan B. Gale, Nicholas J. Holman, David M. Goldenberg
  • ANTIBODY-SN-38 IMMUNOCONJUGATES WITH A CL2A LINKER
    Publication number: 20150306243
    Abstract: The present invention concerns improved methods and compositions for preparing SN-38 conjugates of proteins or peptides, preferably immunoconjugates of antibodies or antigen-binding antibody fragments. More preferably, the SN-38 is attached to the antibody or antibody fragment using a CL2A linker, with 1-12, more preferably 6 or less, most preferably 1-5 SN-38 moieties per antibody or antibody fragment. Most preferably, the immunoconjugate is prepared in large scale batches, with various modifications to the reaction scheme to optimize yield and recovery in large scale. Other embodiments concern optimized dosages and/or schedules of administration of immunoconjugate to maximize efficacy for disease treatment and minimize side effects of administration.
    Type: Application
    Filed: July 1, 2015
    Publication date: October 29, 2015
    Inventors: Serengulam V. Govindan, Jonathan B. Gale, Nicholas J. Holman, David M. Goldenberg
  • Antibody-SN-38 immunoconjugates with a CL2A linker
    Patent number: 9107960
    Abstract: The present invention concerns improved methods and compositions for preparing SN-38 conjugates of proteins or peptides, preferably immunoconjugates of antibodies or antigen-binding antibody fragments. More preferably, the SN-38 is attached to the antibody or antibody fragment using a CL2A linker, with 1-12, more preferably 6 or less, most preferably 1-5 SN-38 moieties per antibody or antibody fragment. Most preferably, the immunoconjugate is prepared in large scale batches, with various modifications to the reaction scheme to optimize yield and recovery in large scale. Other embodiments concern optimized dosages and/or schedules of administration of immunoconjugate to maximize efficacy for disease treatment and minimize side effects of administration.
    Type: Grant
    Filed: April 17, 2014
    Date of Patent: August 18, 2015
    Assignee: Immunimedics, Inc.
    Inventors: Serengulam V. Govindan, Jonathan B. Gale, Nicholas J. Holman, David M. Goldenberg
  • Medical devices including composites
    Patent number: 9011516
    Abstract: Medical devices, such as endoprostheses, and methods of making the devices are described. In some embodiments, a medical device includes an elongated hollow body formed of a polymeric matrix containing one or more regions of a pre-determined weight percent of carbon nanotubes in general alignment in a pre-determined orientation. The medical device can have a compressed state with a first transverse dimension and an expanded state with a second relatively greater transverse dimension.
    Type: Grant
    Filed: June 15, 2007
    Date of Patent: April 21, 2015
    Assignee: Boston Scientific Scimed, Inc.
    Inventors: Jan Weber, Thomas J. Holman, Tracee Eidenschink
  • Reinforced medical balloon
    Patent number: 8852146
    Abstract: The invention relates to medical balloons, and methods of modifying said balloons by forming a void pattern in their exterior surfaces and filling the voids with a material, such as a fiber or a nanomaterial (e.g., nanotubes, such as carbon nanotubes) and a matrix material, e.g., a polymer.
    Type: Grant
    Filed: October 31, 2011
    Date of Patent: October 7, 2014
    Assignee: Boston Scientific Scimed, Inc.
    Inventors: Daniel J. Horn, John Jianhua Chen, Jan Weber, Thomas J. Holman
  • Medical balloon deflation
    Patent number: 8845581
    Abstract: Medical balloons are energetically treated to form regions that facilitate deflation to a desirable configuration.
    Type: Grant
    Filed: November 14, 2006
    Date of Patent: September 30, 2014
    Assignee: Boston Scientific Scimed, Inc.
    Inventors: Thomas J. Holman, Afsar Ali
  • Using bucky paper as a therapeutic aid in medical applications
    Patent number: 8821923
    Abstract: Methods, systems, and uses of bucky paper are provided in the present invention. These embodiments include covering medical implants with single or multiple layers of bucky paper, treating bucky paper with various therapeutics to be released through the bucky paper to a target site, shaping bucky paper into non-conventional configurations for improved therapeutic deliver, and using bucky paper alone or in conjunction with other materials to treat a target site.
    Type: Grant
    Filed: December 12, 2012
    Date of Patent: September 2, 2014
    Assignee: Boston Scientific Scimed, Inc.
    Inventors: Jan Weber, Thomas J. Holman, Tracee Eidenschink, John Jianhua Chen